IGF-1 LR3

IGF-1 LR3 (Long R³ Insulin-Like Growth Factor-1) is a bioengineered analog of human IGF-1 designed for extended biological activity and reduced sequestration by IGF-binding proteins (IGFBPs). In research settings, IGF-1 LR3 is used to probe anabolic signaling, cellular growth and differentiation, glucose handling, and neuromuscular repair paradigms through sustained activation of IGF-1 receptor pathways.

Target: IGF-1 Receptor (IGF-1R, a receptor tyrosine kinase).
Mode: IGF-1 LR3 exhibits markedly reduced affinity for IGFBPs, increasing free ligand availability at the tissue level. Binding to IGF-1R initiates autophosphorylation and downstream PI3K/Akt/mTOR and MAPK/ERK cascades → translational control, protein synthesis, cell survival, and cytoskeletal remodeling.
Functional Notes: Compared with native IGF-1, the LR3 variant demonstrates prolonged receptor engagement and enhanced bioactivity in vitro and in vivo models.

Myotube hypertrophy & satellite-cell activation models • Tissue engineering and wound-healing assays • Metabolic studies on glucose uptake/insulin sensitization • Neurotrophic and neuroprotective inquiry • Cardiovascular remodeling and endothelial function research.

Revitalized Health peptides are produced under cGMP-aligned conditions using pharmaceutical-grade inputs. Each IGF-1 LR3 lot is confirmed at ≥99% purity by HPLC with structure/identity verified via LC-MS/MS. Lots undergo appearance and solubility checks, and microbial/endotoxin screening to research-grade specifications. Certificates of Analysis documenting methods and results are available per batch.

Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor-binding fidelity.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic use. Supplied exclusively to qualified professionals conducting controlled scientific studies.

Identity: Insulin-like growth factor-1 Long Arg³ analog (IGF-1 LR3): 83-aa peptide with Arg substitution at position 3 and extended N-terminus engineered to reduce IGFBP binding and prolong activity.
Mode: Potent IGF-1R agonist with cross-talk to IR/IR-IGF1R hybrids → activates PI3K/AKT (glucose uptake, anti-apoptosis) and MAPK/ERK (proliferation/differentiation). Reduced affinity for IGFBPs increases free fraction and extends receptor engagement compared with native IGF-1; anabolic signaling includes mTOR/S6K phosphorylation and satellite-cell pathways in models.
Analytics/QA: Identity & purity by HPLC/LC-MS; peptide content/counter-ion; sterility (USP <71>) and endotoxin (USP <85>) for parenterals; stability (accelerated/real-time). PD readouts (research): p-AKT/p-ERK Westerns, 2-deoxyglucose uptake, myotube protein synthesis, IGF-1R occupancy/binding, IGFBP displacement assays; metabolic panels (glucose/insulin). Monitoring/Cautions: watch for hypoglycemia (especially fasting or with insulin/secretagogues), edema, arthralgia, carpal-tunnel-like paresthesias; avoid disease-treatment claims on marketing pages.